Rheumnow Podcast

Dr. Cush
  • 1,0 (1)
  • Medicin
  • Varje vecka

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

  1. Podcast Replay: Is it Time to Transition MOAs in RA?

    −8 h

    Podcast Replay: Is it Time to Transition MOAs in RA?

    In August, Dr. Christina Charles-Schoeman and Dr. Manish Jain will return with a new episode exploring the latest clinical data on RA treatment after TNFi failure. Before that episode drops, revisit their 2025 conversation on disease control, real-world data, and guidelines that inform clinical decision-making after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.

    17 min

  2. −4 d

    ICYMI: Great Lectures; Great Presentations

    Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

    28 min

  3. 26 juni

    Generic Tofacitinib (6.26.2026)

    Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

    30 min
  4. DERM on RheumNow (June 2026)

    26 juni

    DERM on RheumNow (June 2026)

    The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr   - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB,  p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8.  Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25).   - Probiotics in Psoriatic Arthritis. (POS0290)    66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks.  This trial proves no significant effect with oral probiotic supplementation in PsA.  - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B

    18 min

  5. 19 juni

    Do You Zoster Vaccinate? (6.19.2026)

    Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

    29 min
  6. RheumNow EULAR 2026 Rheumatology Round Up

    12 juni

    RheumNow EULAR 2026 Rheumatology Round Up

    Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

    56 min
  7. EULAR 2026 RA Topic Panel

    11 juni

    EULAR 2026 RA Topic Panel

    Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.

    54 min
  8. CAR-T Topic Panel EULAR 2026

    10 juni

    CAR-T Topic Panel EULAR 2026

    Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

    38 min
Visa alla (998)

Om

Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com

Information

  • Skapad av
    Dr. Cush
  • Aktiva år
    2016 - 2026
  • Avsnitt
    998
  • Åldersgräns
    Barnvänligt
  • Copyright
    © All rights reserved
  • Programmets webbplats
    Rheumnow Podcast

Du kanske också gillar